Skip to Content

Investor Update

Basel, 21 June 2005

Media Briefing - Pharmacogenomics - the future is now

Roche paving the way for personalised medicine

Roche held a briefing for the media yesterday at their headquarters in Basel.  The topic was “Pharmacogenomics – the future is now.”  The presentations detailed some of the activities in the area of personalised medicine, specifically in pharmacogenomics, which we thought may also be of interest to the financial community.

Speakers and topics at the event included:

Heino von Prondzynski, CEO Division Roche Diagnostics, Basel
Modern Diagnostics – paving the way for personalised medicine

Walter Koch, Vice President, Head of Research, Roche Molecular Diagnostics, Pleasanton
Pharmacogenomics – new tools for improved patient management: AmpliChip CYP450 and Leukemia tests

Prof. Torsten Haferlach, University Hospital Grosshadern, Munich
The impact of molecular profiling on care of patients with blood cancer

James L. Gallarda, Roche Molecular Diagnostics, Pleasanton
The importance of mutation analysis of the p53 tumor suppressor gene

Lyubomir Vassilev, Roche Pharmaceuticals, Nutley
Novel approach to cancer therapy

Presentations slides can be downloaded from the Roche Website, under Media.

We trust that you find these presentations of interest. If you have any additional questions, please contact us.

About Roche
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is a world leader in Diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2004, sales by the Pharmaceuticals Division totalled 21.7 billion Swiss francs, while the Diagnostics Division posted sales of 7.8 billion Swiss francs. Roche employs roughly 65,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Additional information about the Roche Group is available on the Internet (www.roche.com).